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ABSTRACT
Objective: Reduced exercise capacity is well
documented in end-stage chronic kidney disease
(CKD), preceded by changes in cardiac morphology in
CKD stage 3. However, it is unknown whether
subclinical cardiopulmonary dysfunction occurs in CKD
stage 3 independently of heart failure.
Methods: Prospective observational cross-sectional
study of exercise capacity assessed by
cardiopulmonary exercise testing in 993 preoperative
patients. Primary outcome was peak oxygen
consumption (VO2peak). Anaerobic threshold (AT),
oxygen pulse and exercise-evoked measures of
autonomic function were analysed, controlling for CKD
stage 3, age, gender, diabetes mellitus and
hypertension.
Results: CKD stage 3 was present in 93/993 (9.97%)
patients. Diabetes mellitus (RR 2.49 (95% CI 1.59 to
3.89); p<0.001), and hypertension (RR 3.20 (95% CI
2.04 to 5.03); p<0.001)) were more common in CKD
stage 3. Cardiac failure (RR 0.83 (95% CI 0.30 to
2.24); p=0.70) and ischaemic heart disease (RR 1.40
(95% CI 0.97 to 2.02); p=0.09) were not more
common in CKD stage 3. Patients with CKD stage 3
had lower predicted VO2peak (mean difference: 6%
(95% CI 1% to 11%); p=0.02), lower peak heart rate
(mean difference:9 bpm (95% CI 3 to 14); p=0.03)),
lower AT (mean difference: 1.1 mL/min/kg (95% CI 0.4
to 1.7); p<0.001) and impaired heart rate recovery
(mean difference: 4 bpm (95% CI 1 to 7); p<0.001)).
Conclusions: Subclinical cardiopulmonary
dysfunction in CKD stage 3 is common. This study
suggests that maladaptive cardiovascular/autonomic
dysfunction may be established in CKD stage 3,
preceding pathophysiology reported in end-stage CKD.
INTRODUCTION
Chronic kidney disease (CKD) is associated
with increased cardiovascular risk1 and mortal-
ity2 and increased incidence of cardiac
failure.3–5 Reduced exercise capacity in patients
with end-stage renal disease6 is associated with
poor survival.7–9 In patients with end-stage
renal disease, the combination of increased left
ventricular mass, myocardial ﬁbrosis, elevated
left ventricular ﬁlling pressure and arterial stiff-
ness are associated with reduced exercise cap-
acity.10 Similarly, autonomic abnormalities have
been described in end-stage (haemodialysis-
dependent) CKD.11 12 By contrast, there is sur-
prisingly few data on the association between
impaired cardiac and/or autonomic function
in asymptomatic patients with early CKD (CKD
stage 3). Although changes in cardiac structure
occur at different stages of estimated glomeru-
lar ﬁltration rate (eGFR),13 no signiﬁcant asso-
ciations between kidney function and systolic
or diastolic cardiac function have been found
even after adjusting for potential confounding
variables.13 In this prospective, cross-sectional
observational study, we hypothesised that sub-
clinical cardiopulmonary dysfunction in CKD
stage 3 may be unmasked by objectively asses-
sing cardiopulmonary reserve using cardiopul-
monary exercise testing (CPET).
METHODS
IRB approval (MREC: 12/LO/0453) was
obtained in accordance with the Declaration
of Helsinki. Adherence to STROBE
KEY QUESTIONS
What is already known about this subject?
▸ Early chronic kidney disease (CKD) is associated
with structural cardiac changes, but the func-
tional significance of this has not been explored.
What does this study add?
▸ Using cardiopulmonary exercise testing, we
show that early CKD is associated with subclin-
ical, inferior cardiopulmonary reserve and evi-
dence for autonomic dysfunction.
How might this impact on clinical practice?
▸ These data contribute new insights into why
early CKD appears to be associated with worse
clinical outcomes across a range of clinical
scenarios, including percutaneous coronary
intervention, cardiac and non-cardiac surgery.
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guidelines is documented in online supplementary
material. Patients were enrolled prospectively at
University College London Hospitals, UK (from
December 2007 to May 2014), referred by their clinical
team for CPET as part of routine standard-of-care pre-
operative assessment. Patients gave written consent to
use CPET data. Exclusion criteria for CPET were in
accordance with international guidelines.14 Adherence
to STROBE guidelines is documented in the online sup-
plementary material.
CKD assessment
eGFR was calculated from routine preoperative creatin-
ine measurements using the modiﬁcation of diet in
renal disease (MDRD) equation,15 in line with most pre-
vious perioperative studies in the non-cardiac surgical
populations. As we were primarily interested in categoris-
ing eGFR<60 mL/min/1.73 m2, potential inaccuracy of
MDRD at higher levels of GFR was not a major consider-
ation. CKD stage was deﬁned from eGFR according to
Kidney Disease: Improving Global Outcomes (KDIGO)
2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. As data on urin-
alysis and cystatin C was not available for the purposes of
this study, presence of CKD stage 3 was deﬁned as eGFR
45–60 mL min.1.73 m2.
CPET performance
Investigators blinded to CKD stage carried out all exer-
cise testing. Equipment was calibrated before each test
using standard reference gases. Patients undertook
CPET on an electronically controlled cycle ergometer
(Zan, nSpire, Colorado, USA; Lode, Groningen, The
Netherlands) to maximal tolerance, adhering to the
timed protocol detailed in online supplementary ﬁgure
S1. Continuous 12-lead ECG was recorded. Continuous
breath-by-breath gas exchange analysis was performed,
with on-line calculations of oxygen consumption (VO2;
mL/kg/min), minute ventilation (VE), carbon dioxide
production (VCO2) and respiratory exchange ratio
(RER; VCO2/VO2). Before each test, the pneumotach-
ometer was referenced by calibrating the gas analysers
with a certiﬁed air mixture, according to the manufac-
turer’s speciﬁcations. All patients were instructed to con-
tinue cycling until symptom-limited fatigue. CPET data
were analysed blinded to CKD status. Anaerobic thresh-
old (AT) was determined by two independent assessors
blinded to autonomic parameters, and according to
published guidelines using the modiﬁed V-slope
method, and conﬁrmed by ventilatory equivalents for
carbon dioxide ( _VE= _VCO2) and oxygen ( _VE= _VO2).
16 17
Peak oxygen consumption ( _VO2peak ), oxygen pulse and
_VE= _VCO2 were also recorded. _VE= _VCO2 is inversely
related to cardiac output at peak exercise,18 and is a
better predictor of outcome in heart failure.19 Predicted
values, derived from population norms that take into
account age, gender, weight and height, were calculated
for _VO2peak
20 and oxygen pulse,21 a robust measure of left
ventricular stroke volume.22 23 Per cent predicted peak
_VO2 values (derived from the Wasserman/Hansen equa-
tions) are a superior measure of these variables, at least
in patients with established heart failure.24
Assessment of exercise-evoked ischaemia
Continuous 12-lead ECG recordings were made through-
out the CPET period to enable the detection of ischae-
mia and/or development of dysrhythmias. ST-segment
depression was quantiﬁed in lead II, which is superior
for detection of atrial dysrhythmias, and more easily
obtained with conventional monitors.25 Lead II ST
changes were deﬁned as abnormal when ST depression
of 0.1 mV (1 mm) or more occurred, in accordance with
current American College of Cardiology guidelines,26
and consistent with previous studies identifying that
ST-segment depression to levels ≥1 mm independently
predict future cardiac events in asymptomatic
populations.27
Autonomic assessment
Autonomic data were analysed ofﬂine, blinded to CKD
status and postoperative outcomes. Exercise-evoked sym-
pathetic and parasympathetic autonomic responses were
assessed following the CPET protocol as described
above. Patients undertook 3 min of unloaded pedalling
prior to the initiation of ramped exercise. Heart rate
readings were obtained via ECG with the patient sitting
on the cycle ergometer. All patients acclimatised for
3 min on the ergometer prior to start exercise.
Non-invasive blood pressure was measured at the start
(zero workload) and at the end of CPET. Sympathetic
dysfunction was deﬁned as the early acceleration of
heart rate prior to exercise (AHRR), that is, the differ-
ence between the heart rate at rest and the heart rate
measured just before starting loaded pedalling during
the exercise test protocol (ie, after 3 min of unloaded
exercise). Parasympathetic dysfunction was deﬁned from
heart rate recovery at 1 min following the cessation of
exercise. We deﬁned an abnormal heart rate recovery as
a failure to decrease heart rate by ≥12 bpm 1 min after
the end of exercise, based on extensive previous data
showing an association between heart rate recovery and
an increased risk of cardiovascular and all-cause cardio-
vascular death.28 29
Statistics
The primary outcome was _VO2peak . Secondary outcomes
were AT, _VE= _VCO2 , oxygen pulse, anticipatory heart rate
and heart rate recovery. Baseline characteristics of parti-
cipants were compared according to presence of CKD
stage 3 using general linear models of analysis of vari-
ance (quantitative variables), controlling for age as a
covariate where CPET variables are not referenced to
population norms. Non-parametric data were analysed
with the Kruskal-Wallis test. Categorical variables were
analysed using Fisher’s exact test. Multivariate analysis to
establish clinical predictors of peak VO2 took into
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account age (continuous variable) and the following cat-
egorical variables: gender, malignancy, hypertension,
cardiac failure, diabetes mellitus and CKD stage 3. All
reported p values are two sided, with signiﬁcance set at
p≤0.05. Statistical analyses were performed using NCSS
8 (Kaysville, Utah, USA).
Sample size calculation
On the basis of previous cardiac structural studies, a
prevalence of 48% left ventricular hypertrophy (LVH)
occurs in CKD stage 3, versus 32% in patients with
normal renal function. Approximately 10% of UK
patients have CKD in the general population. We esti-
mated that LVH would mirror the degree of impaired
exercise performance; therefore, to detect a similar dif-
ference in lower-than-normal predicted _VO2peak , a sample
size ≥853 patients was required (α of 0.05; power of
80%). A 10% dropout rate was anticipated for patients
in whom AT was difﬁcult to assess, or who failed to com-
plete CPET for medical reasons (arrhythmia, (pre-)
syncope).
RESULTS
Clinical characteristics
We analysed CPET data for 933 patients (ﬁgure 1). CKD
stage 3 was present in 93/933 (9.97%) patients.
Demographics for patients are shown in table 1, strati-
ﬁed by the presence/absence of CKD stage 3. Patients
were well matched for biochemical biomarkers
synonymous with advanced CKD and increased risk of
cardiovascular disease,30 namely, similar haemoglobin
and albumin levels. Diabetes mellitus (RR 2.49 (95% CI
1.59 to 3.89); p<0.001), and hypertension (RR 3.20
(95% CI 2.04 to 5.03); p<0.001)) were more prevalent in
CKD stage 3. However, clinically diagnosed/treated
cardiac failure (RR 0.83 (95% CI 0.30 to 2.24); p=0.70)
and ischaemic heart disease (RR 1.40 (95% CI 0.97 to
2.02); p=0.09) were not more prevalent in CKD3.
Functional cardiovascular reserve in CKD3 versus normal
renal function
Cardiopulmonary parameters measured during exercise
are summarised in table 2. Consistent with their clinical
cardiovascular phenotype, neither left ventricular stroke
volume (predicted oxygen pulse; mean difference: 6%
(−2 to 13); p=0.33) nor exercise-evoked ischaemia dif-
fered between patients with CKD3 and normal renal
function. These data were consistent with a low preva-
lence of clinically diagnosed heart failure (<5% in both
groups).
However, despite a similar prevalence of overt cardio-
vascular disease, CPET revealed that patients with CKD
stage 3 had lower predicted values for AT and VO2peak,
which control for age, gender, weight and height.
Predicted VO2peak (mean difference: 6% (95% CI 1% to
11%); p=0.02) and lower AT (mean difference: 1.1 mL/
min/kg (95% CI 0.4 to 1.7); p=0.002) were lower in
patients with CKD stage 3. Ventilatory equivalents for
carbon dioxide ( _VE= _VCO2), a powerful predictor of prog-
nosis in clinically diagnosed heart failure, was substan-
tially higher in patients with CKD stage 3 (mean
difference: 3.5 (95% CI 2.4 to 4.6); p<0.001). Taken
together, these data suggest that patients with CKD stage
3 have occult cardiovascular dysfunction that is not
revealed by clinical history or routine tests.
Autonomic characteristics of CKD3
Online supplementary ﬁgure S1 summarises measures
of heart rate dynamics made during CPET over time in
patients with normal renal function and those with CKD
stage 3. Similar resting heart rates were evident in
patients with normal renal function and those with CKD
stage 3. Table 3 summarises individualised changes in
absolute heart rate indicative of sympathetic (peak and
anticipatory) and parasympathetic (recovery) autonomic
function. Patients with CKD stage 3 had lower peak
heart rates attained during exercise (mean difference:
9 bpm (95% CI 3 to 14); p=0.002)) and impaired heart
rate recovery (HRR; online supplementary ﬁgure S1)
from peak exercise heart rate (mean difference: 4 bpm
(95% CI 1 to 7); p=0.003)). Controlling for age, the
smaller increases in peak heart rate from baseline (rise;
ﬁgure 1), and lower heart rate recovery observed in
patients with CKD stage 3 remained signiﬁcant. Heart
rate recovery in patients with CKD stage 3 was more
likely to fall below 12 bpm (relative risk: 1.51 (95% CI
1.17 to 1.96); p<0.001), a threshold value which has
Figure 1 Study analysis plan. CKD, chronic kidney disease;
CPET, cardiopulmonary exercise testing; eGFR, estimated
glomerular filtration rate; ITT, intention to treat.
Nelson A, Otto J, Whittle J, et al. Open Heart 2016;3:e000370. doi:10.1136/openhrt-2015-000370 3
Special populations
been shown to be an independent predictor of all-cause
and cardiovascular-related mortality.28 29 Anticipatory
heart rate (AHRR; online supplementary ﬁgure S1)
during unloaded pedalling, a measure of sympathetic
dysfunction,31 was similar between groups.
Functional cardiovascular reserve in CKD3 with/without
essential hypertension
End-stage CKD is associated with lower exercise capacity
compared to patients with hypertension.6 On subgroup
analysis, we found that patients with CKD stage 3
without hypertension had lower exercise capacity com-
pared to non-hypertensive patients with normal renal
function (n=516; table 4). Similar results were obtained
for patients with CKD stage 3 without diabetes mellitus
(see online supplementary data). Multivariate analysis
identiﬁed CKD stage 3 and pre-existing cardiac failure as
independent predictors of VO2peak (table 5), taking into
account coexistence of diabetes mellitus and
hypertension.
DISCUSSION
These data show that CPET reveals subclinical differ-
ences in cardiopulmonary physiology in patients with
CKD stage 3. Patients with CKD stage 3 did not have
overt clinical histories or evidence for inferior cardiovas-
cular performance. These data are the ﬁrst to demon-
strate that early CKD is associated with impaired
cardiopulmonary reserve in the absence of known sys-
tolic heart failure. Importantly, our analyses used popu-
lation norms for cardiopulmonary exercise performance
controlling for age and gender, in contrast with a com-
parable study exploring the relationship between CKD
and exercise capacity in patients with known systolic
heart failure.10 Furthermore, these cardiopulmonary dif-
ferences appear to precede established biomarkers for
Table 1 Preoperative demographics/comorbidities for study population
eGFR >60 CKD stage 3 p Value
n 840 93
Age (years) 61 (59 to 61) 71 (69 to 73) <0.001
Gender (n; % male) 546 (65) 69 (74) 0.08
BMI (kg/m2) 26.7 (26.3 to 27.1) 27.4 (26.3 to 28.5) 0.24
Cancer (n (%)) 360 (43) 34 (37) 0.34
Ischaemic heart disease (n (%)) 156 (19) 24 (26) 0.08
Hypertension (n (%)) 252 (30) 51 (55) <0.001
Heart failure (n (%)) 44 (5) 4 (4) 0.44
CVA/TIA (n (%)) 20 (2) 4 (4) 0.31
Diabetes mellitus (n (%)) 71 (9) 20 (22) <0.001
Haemoglobin (g/dL) 13.3 (13.0 to 13.5) 12.9 (12.5 to 13.3) 0.39
Albumin (g/L) 44±4 44±4 0.81
Lung disease/COPD (n (%)) 98 (13) 15 (16) 0.49
Smoker (ex/present; n (%) 291 (35) 36 (39) 0.55
β-blocker (n (%)) 85 (10) 13 (14) 0.20
Nitrate (n (%)) 24 (3) 5 (5) 0.16
ACE inhibitor (n (%)) 119 (14) 26 (28) <0.001
Statin (n (%)) 184 (22) 34 (37) <0.001
Data are shown as n (%) or mean (95% CIs).
BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebral vascular accident; eGFR,
estimated glomerular filtration rate; TIA, transient ischemic attack.
Table 2 CPET performance for study population
eGFR>60 CKD stage 3 p Value
VO2peak (mL/min kg) 17.7±5.6 14.9±4.1 <0.001
VO2peak (% predicted) 76±25 69±18 0.02
VO2AT (mL/min kg) 11.4±2.2 10.4±2.2 <0.001
VE-VCO2 slope 30.3±5.9 33.8±5.9 <0.001
Oxygen pulse
(mL/min O2)
10.2±4.2 9.1±2.6 0.35
Oxygen pulse
(% predicted)
90.6±26 85.1±21 0.35
Data are shown as mean (SD). All % predicted values control for
age, gender, weight.
AT, Anaerobic threshold; CKD, chronic kidney disease; CPET,
cardiopulmonary exercise testing; eGFR, estimated glomerular
filtration rate; VCO2, carbon dioxide production; VE, ventilation;
VO2peak, peak oxygen consumption.
Table 3 Dynamic heart rate changes during CPET
eGFR>60 CKD stage 3 p Value
Baseline heart rate 84±15 85±16 0.49
Anticipatory heart rate 11±10 12±9 0.15
Peak heart rate 138±24 130±20 0.002
Heart rate rise 57±24 45±21 <0.001
Heart rate recovery
at 1 min
19±13 15±8 0.001
Data are shown as mean (SD).
CKD, chronic kidney disease; CPET, cardiopulmonary exercise
testing; eGFR, estimated glomerular filtration rate.
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cardiovascular disease in more advanced CKD, including
albumin and haemoglobin.30 These ﬁndings suggest
that impaired exercise performance begins at a much
earlier stage of CKD in keeping with cardiac structural
insights provided by echocardiography.13 Although
approximately half the patients studied had malignancy,
this was not associated with the inferior exercise per-
formance evident in CKD stage 3.
CKD increases the risk of acquiring32 33 and acceler-
ates the progression of chronic heart failure.34–37 The
pathophysiology of cardiorenal syndromes is a complex
bidirectional process. Our ﬁndings provide functional
physiological data using a gold standard assessment of
cardiopulmonary functions that are consistent with pre-
vious morphological studies detailing subclinical cardiac
abnormalities in CKD.13 Left ventricular hypertrophy is
more common in patients with CKD, which has previ-
ously been thought to precede functional impairment.35
These structural differences appear to be driven by pro-
gressive CKD, in part, accounted for by the increased
prevalence of diabetes mellitus and hypertension in
CKD. Our data are consistent with recent epidemio-
logical work showing that CKD confers greater risk of
cardiovascular disease than diabetes,38 since patients
with diabetes in this cohort free of CKD had superior
cardiopulmonary exercise performance. Our data
suggest that CKD has a further negative impact on poor
cardiovascular function.
Because the prevalence of hypertension in patients
with CKD is very common, we also compared patients
free of, or with established, hypertension. In this large
subset, we conﬁrmed the overall ﬁndings that patients
with CKD stage 3 without hypertension had lower exer-
cise capacity compared to non-hypertensive controls.
Furthermore, analysis of exercise-evoked changes in
heart rate revealed distinct autonomic proﬁles in CKD
stage 3. The ﬁnding that peak heart rate was impaired
mirrors a similar observation in patients with end-stage
CKD, in whom a blunted chronotropic response was an
independent predictor of peak VO2.
6 Furthermore,
impaired parasympathetic dysfunction—as suggested by
slower heart rate recovery in patients CKD—has
emerged as an important contributor to myocardial
injury,39 systemic inﬂammation40 and progression of
CKD.41 42 Interestingly, patients with CKD stage 3 were
more likely to have an HRR value previously shown to
predict mortality and development of signiﬁcant cardio-
vascular morbidity/mortality.28 29
Signiﬁcant limitations include the observational cross-
sectional nature of the study which prevents more robust
conclusions regarding causality, particularly given
limited information on the duration of key comorbid
conditions including hypertension and diabetes.
Echocardiographic correlates of exercise performance
may provide further structural and functional insights,
although static measures would not provide the depth of
physiological insight afforded by CPET. Strengths of
these data are reﬂected by the large data set, blinded
study design, appropriately powered analysis plan, and
established biological plausibility for the cardiovascular
phenotypes described.
There are several clinical implications generated by
these data. The presence of CKD stage 3 should alert
clinicians to early CKD being a surrogate marker for
poorer cardiac output under stress. CKD stage 3 is asso-
ciated with poorer outcomes following major non-
cardiac and cardiac surgery.43 Thus, acute blood loss,
hypotension44 and/or hypovolemia in patients with CKD
stage 3 may confer additional increased risk of
pan-organ and further renal injury as a result of inferior
cardiovascular performance. Further studies are
required to determine whether the exercise phenotype
maps to inferior cardiovascular performance in various
clinical situations.
In summary, patients with CKD stage 3, but without
clinical heart failure, have signiﬁcantly worse cardiovas-
cular function when challenged with standardised, pro-
tocolised physiological stress. In addition to the higher
Table 4 CPET characteristics of non-hypertensive
patients with/without CKD stage 3
eGFR>60 CKD stage 3 p Value
VO2peak (mL/min kg) 18.7±5.9 15.2±4.4 0.001
VO2peak (% predicted) 75±24 66±16 0.02
VO2AT (mL/min kg) 11.7±3.1 10.6±2.7 0.01
VE-VCO2 slope 29.7±4.9 34.8±6.6 <0.001
Oxygen pulse
(mL/min O2)
10.3±4.6 8.9±3.1 0.21
Oxygen pulse
(% predicted)
90±28 82±23 0.21
Peak heart rate (bpm) 142±24 131±19 0.02
Heart rate
recovery (bpm)
20±13 16±9 0.05
Data are shown mean (SD). All % predicted values control for
age, gender, weight.
AT, Anaerobic threshold; CKD, chronic kidney disease; CPET,
cardiopulmonary exercise testing; eGFR, estimated glomerular
filtration rate; VCO2, carbon dioxide production; VE, ventilation;
VO2peak, peak oxygen consumption.
Table 5 Multivariate analysis of clinical predictors for
peak VO2
95% CL
Independent
variable
Regression
coefficient Lower Upper
p
Value
Intercept 74.9678 72.4250 77.5106 0.01
Cancer 1.2933 −2.0560 4.6426 0.45
Cardiac failure −20.1919 −35.3029 −5.0810 0.01
CKD stage 3 −6.2930 −11.9994 −0.5866 0.03
Diabetes
mellitus
−4.9127 −10.5744 0.7491 0.09
Hypertension 0.7507 −2.9437 4.4451 0.69
CKD, chronic kidney disease; CL, confidence limit; VO2 oxygen
consumption.
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prevalence of diabetes mellitus and hypertension
evident in patients with CKD stage 3, the subclinical dys-
functional cardiopulmonary phenotype described here
provides additional pathophysiological mechanisms that
may contribute to poorer clinical outcomes following
acute cardiometabolic stress.
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